Hostname: page-component-77c89778f8-5wvtr Total loading time: 0 Render date: 2024-07-16T09:15:08.740Z Has data issue: false hasContentIssue false
  • English
  • Français

Defects in long chain fatty acid oxidation presenting as severe cardiomyopathy and cardiogenic shock in infancy

Published online by Cambridge University Press:  20 August 2009

Narendra R. Dereddy ,
David Kronn  and
Usha Krishnan
Narendra R. Dereddy
Affiliation:
Department of Pediatrics, Maria Fareri Children’s Hospital, Westchester Medical Center, Valhalla, New York, United States of America
David Kronn
Affiliation:
Department of Metabolic and Genetic Disorders, Maria Fareri Children’s Hospital, Westchester Medical Center, Valhalla, New York, United States of America
Usha Krishnan*
Affiliation:
Department of Pediatric Cardiology, Maria Fareri Children’s Hospital, Westchester Medical Center, Valhalla, New York, United States of America
*
Correspondence to: Usha Krishnan, MD, Division of Pediatric Cardiology, 618, Munger Pavilion, New York Medical College, Valhalla, NY 10595, United States of America. Tel: 1-914-493-8372; Fax: 914-594-4513; E-mail: usha_krishnan@nymc.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Inborn errors of fatty acid metabolism are important causes of reversible cardiomyopathy in infancy. Disorders in long chain fatty acid oxidation can lead to cardiomyopathy, as fatty acid beta oxidation is the major source of myocardial energy after birth. We present 2 cases of such disorders with cardiac manifestations during infancy, which responded well to a diet low in long chain fatty acids.

Keywords

Heart failurelipid metabolismpericardial effusion
Type
Brief Report
Information
Cardiology in the Young , Volume 19 , Issue 5 , October 2009 , pp. 540 - 542
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Ferencz, C, Neill, CA. Cardiomyopathy in infancy: observations in an epidemiological study. Pediatr Cardiol 1992; 13: 65–71.CrossRefGoogle Scholar
2. Lewis, AW, Chabot, M. Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol 1991; 68: 365–369.CrossRefGoogle ScholarPubMed
3. Mathur, A, Sims, H, Gopalakrishnan, D, et al. Molecular heterogeneity in very-long-chain acyl-coA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 1999; 99: 1337–1343.CrossRefGoogle ScholarPubMed
4. Brown-Harrison, MC, Nada, MA, Sprecher, H, et al. Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 1996; 58: 59–65.CrossRefGoogle ScholarPubMed
5. Cox, GF, Souri, M, Aoyama, T, et al. Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1998; 133: 247–253.CrossRefGoogle ScholarPubMed
6. Spiekerkoetter, U, Tenenbaum, T, Heusch, A, Wendel, U. Cardiomyopathy and pericardial effusion in infancy point to a fatty acid beta oxidation defect after exclusion of an underlying infection. Pediatr Cardiol 2003; 24: 295–297.CrossRefGoogle Scholar
7. Liebeg, M, Schymik, I, Mueller, M, et al. Neonatal screening for very long-chain acyl-CoA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C 14:1-carnitine levels. Pediatrics 2006; 118: 1065–1069.CrossRefGoogle Scholar
8. Boneh, A, Andresen, BS, Gregersen, N, et al. VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 2006; 88: 166–170.CrossRefGoogle ScholarPubMed